alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
132 STAT. 4380 PUBLIC LAW 115–296—DEC. 6, 2018 

LEGISLATIVE HISTORY—H.R. 5935: 

CONGRESSIONAL RECORD, Vol. 164 (2018): 

Sept. 13, considered and passed House. 

Nov. 15, considered and passed Senate. 

Æ 

Public Law 115–296 

115th Congress 

An Act 

To designate the facility of the United States Postal Service located at 1355 North 

Meridian Road in Harristown, Illinois, as the ‘‘Logan S. Palmer Post Office’’. 

Be it enacted by the Senate and House of Representatives of 

the United States of America in Congress assembled, 

SECTION 1. LOGAN S. PALMER POST OFFICE. 

(a) DESIGNATION.—The facility of the United States Postal 

Service located at 1355 North Meridian Road in Harristown, Illinois, 

shall be known and designated as the ‘‘Logan S. Palmer Post 

Office’’. 

(b) REFERENCES.—Any reference in a law, map, regulation, 

document, paper, or other record of the United States to the facility 

referred to in subsection (a) shall be deemed to be a reference 

to the ‘‘Logan S. Palmer Post Office’’. 

Approved December 6, 2018. 

Dec. 6, 2018 

[H.R. 5935] 


ralbany on LAP520R082 with PUB LAWS PDF
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
COMPANY'S DECEMBER 31, 1998 FINANCIAL STATEMENTS AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1998
<PERIOD-START>                             JAN-01-1998
<PERIOD-END>                               DEC-31-1998
<CASH>                                          17,476
<SECURITIES>                                     1,000
<RECEIVABLES>                                   40,884
<ALLOWANCES>                                     2,580
<INVENTORY>                                      6,747
<CURRENT-ASSETS>                                74,537
<PP&E>                                         390,505
<DEPRECIATION>                                 116,326
<TOTAL-ASSETS>                                 494,055
<CURRENT-LIABILITIES>                          120,750
<BONDS>                                        462,079
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             4
<OTHER-SE>                                    (90,026)
<TOTAL-LIABILITY-AND-EQUITY>                   494,055
<SALES>                                         56,838
<TOTAL-REVENUES>                               311,652
<CGS>                                           69,150
<TOTAL-COSTS>                                  125,734
<OTHER-EXPENSES>                                43,420
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              43,798
<INCOME-PRETAX>                               (41,710)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                           (41,710)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                               (17,606)
<CHANGES>                                            0
<NET-INCOME>                                  (59,316)
<EPS-PRIMARY>                                   (1.47)
<EPS-DILUTED>                                   (1.47)
        

</TABLE>
§ 700.19 Use of methylene chloride as an ingredient of cosmetic products. ( a ) Methylene chloride has been used as an ingredient of aerosol cosmetic products, principally hair sprays, at concentrations generally ranging from 10 to 25 percent. In a 2-year animal inhalation study sponsored by the National Toxicology Program, methylene chloride produced a significant increase in benign and malignant tumors of the lung and liver of male and female mice. Based on these findings and on estimates of human exposure from the customary use of hair sprays, the Food and Drug Administration concludes that the use of methylene chloride in cosmetic products poses a significant cancer risk to consumers, and that the use of this ingredient in cosmetic products may render these products injurious to health.
( b ) Any cosmetic product that contains methylene chloride as an ingredient is deemed adulterated and is subject to regulatory action under sections 301 and 601(a) of the Federal Food, Drug, and Cosmetic Act.
[54 FR 27342, June 29, 1989]
# C_2014235EN.01000201.xml

| 21.7.2014 | EN | Official Journal of the European Union | C 235/2 |
| --- | --- | --- | --- |

21.7.2014

EN

Official Journal of the European Union

C 235/2

---

Request for a preliminary ruling from the Finanzgericht Berlin-Brandenburg (Germany) lodged on 26 March 2014 — TMK Europe GmbH v Hauptzollamt Frankfurt (Oder)

(Case C-143/14)

2014/C 235/02

Language of the case: German

Referring court

Referring court

Finanzgericht Berlin-Brandenburg

Parties to the main proceedings

Parties to the main proceedings

Applicant: TMK Europe GmbH

Applicant:

Defendant: Hauptzollamt Frankfurt (Oder)

Defendant:

Question referred

Question referred

Is Council Regulation (EC) No 2320/97 (1) of 17 November 1997 imposing definitive anti-dumping duties on imports of certain seamless pipes and tubes of iron or non-alloy steel originating in Hungary, Poland, Russia, the Czech Republic, Romania and the Slovak Republic, repealing Regulation (EEC) No 1189/93 and terminating the proceeding in respect of such imports originating in the Republic of Croatia invalid because the Commission, in breach of the requirements applicable to the determination of injury laid down in Article 3(7) of Council Regulation (EC) No 384/96 (2) of 22 December 1995 on protection against dumped imports from countries not members of the European Community, assumed such (injury) to exist without taking into account in this regard the fact that, pursuant to an unpublished decision of 25 November 1994 (Case IV/35.304), adopted on the basis of, inter alia, Article 14(3) of Council Regulation No 17 of 6 February 1962, First Regulation implementing Articles 81 EC and 82 EC (OJ English Special Edition 19591962, p. 87), the Commission had carried out an investigation into the possible existence of anti-competitive practices concerning pipes and tubes of non-alloy steel which might possibly infringe Article 53 of the Agreement on the European Economic Area of 2 May 1992 (OJ 1994 L 1, pp. 3 to 522) and Article 81 EC?

1

2

---

(1)  OJ 1997 L 322, p. 1.

1

(2)  OJ 1996 L 56, p. 1.

2

---
**Exhibit 23.1**

 

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

 

We consent to the incorporation by reference in Registration Statement Nos. 333-118125, 333-111978, 333-108617, 333-81208,333-71954, 333-70976, 333-60132, 333-43038, 333-40322 and 333-35876 on Form S-3 and Nos. 333-108619, 333-70982, 333-38964 and 333-35874 on Form S-8 of GlycoGenesys, Inc. of our report dated March 29, 2005 (which report expresses an unqualifiedopinion and includes an explanatory paragraph referring to the Company’s ability to continue as a going concern), relating to the consolidated financial statements of GlycoGenesys, Inc., appearing in this Annual Report on Form 10-K ofGlycoGenesys, Inc. for the year ended December 31, 2004. 

 

/s/    Deloitte & Touche LLP 

 

Boston,Massachusetts 

March 29, 2005
#### Fairfield County Trust Company *v.*Abe Steinbrecher

*Sidney Vogel,*in support of the petition.

*Lawrence P. Dennin, Jr.,*in opposition.

Submitted January 16

decided February 4, 1969

The petition by the defendant for certification for appeal from the Appellate Division of the Circuit Court is denied.
**Exhibit31.1**

**CERTIFICATIONS**

I, Alan Kiraly, certifythat:

1. I have reviewed thisquarterly report on Form 10-Q of Enterprise Informatics Inc.;

2. Based on my knowledge,this quarterly report does not contain any untrue statement of a material factor omit to state a material fact necessary to make the statements made, inlight of the circumstances under which such statements were made, notmisleading with respect to the period covered by this quarterly report;

3. Based on my knowledge,the financial statements, and other financial information included in thisquarterly report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this quarterly report;

4. The registrant’s othercertifying officer(s) and I are responsible for establishing and maintainingdisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and have:

a) designed suchdisclosure controls and procedures, or caused such disclosure controls andprocedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this quarterly report is being prepared;

b) evaluated theeffectiveness of the registrant’s disclosure controls and procedures andpresented in this quarterly report our conclusions about the effectiveness ofthe disclosure controls and procedures, as of the end of the period covered bythis quarterly report based on such evaluation; and

c) disclosed in thisquarterly report any change in the registrant’s internal control over financialreporting that occurred during the registrant’s most recent fiscal quarter (theregistrant’s fourth fiscal quarter in the case of an annual report) that hasmaterially affected, or is reasonably likely to materially affect, theregistrant’s internal control over financial reporting; and

5. The registrant’s othercertifying officer(s) and I have disclosed, based on our most recent evaluationof internal control over financial reporting, to the registrant’s auditors andthe audit committee of the registrant’s board of directors (or personsperforming the equivalent functions):

a) all significantdeficiencies and material weaknesses in the design or operation of internalcontrol over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize and reportfinancial information; and

b) any fraud, whether ornot material, that involves management or other employees who have asignificant role in the registrant’s internal control over financial reporting
| Dated:  May 15,  2007 |
|---------------------------------|
|                            |
| /s/ Alan Kiraly                 |   |   |
| Alan Kiraly                     |
|                            |
| Chief Executive  Officer        |

 

1

----
<PAGE>
 
                                                                      EXHIBIT 21
                                                                      ----------

                        SUBSIDIARIES OF THE REGISTRANT

<TABLE> 
<CAPTION> 

                                                      Jurisdiction          
       Subsidiaries (a)                               of Incorporation      
       ------------                                   ----------------      
<S>                                                   <C> 
Victoria's Secret Stores, Inc. (b)                    Delaware              
Cacique, Inc. (c)                                     Delaware              
Victoria's Secret Catalogue, Inc. (d)                 Delaware              
Bath & Body Works, Inc. (e)                           Delaware              
Gryphon Development, Inc. (f)                         Delaware              
Intimate Brands Service Corporation (g)               Delaware               
</TABLE> 

(a)  The names of certain subsidiaries are omitted since such unnamed
     subsidiaries, considered in the aggregate as a single subsidiary, would not
     constitute a significant subsidiary as of February 1, 1997.

(b)  Victoria's Secret Stores, Inc. is a wholly-owned subsidiary of Victoria's
     Secret Stores Holding Corporation, a Delaware corporation and a wholly-
     owned subsidiary of the registrant.

(c)  Cacique, Inc. is a wholly-owned subsidiary of Cacique Holding Corporation,
     a Delaware corporation and a wholly-owned subsidiary of the registrant.

(d)  Victoria's Secret Catalogue, Inc. is a wholly-owned subsidiary of
     Victoria's Secret Catalogue  Holding Corporation, a Delaware corporation
     and a wholly-owned subsidiary of the registrant.

(e)  Bath & Body Works, Inc. is a wholly-owned subsidiary of Bath and Body Works
     Holding Corporation, Inc., a Delaware corporation and a wholly-owned
     subsidiary of the registrant.

(f)  Gryphon Development, Inc. is a wholly-owned subsidiary of the Gryphon
     Holding Corporation, a Delaware corporation and a wholly-owned subsidiary
     of the registrant.

(g)  Intimate Brands Service Corporation is a wholly-owned subsidiary of the
     registrant.
Exhibit 31.2
 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER
PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
     (a)
    
    Designed such disclosure controls and procedures, or caused such disclosure controls
and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by
others within those entities, particularly during the period in which this report is being
prepared;(b)
    
    Designed such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision, to provide
reasonable assurance regarding the reliability of financial reporting and the preparation
of financial statements for external purposes in accordance with generally accepted
accounting principles;(c)
    
    Evaluated the effectiveness of the registrants disclosure controls and procedures and
presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such
evaluation; and(d)
    
    Disclosed in this report any change in the registrants internal control over financial
reporting that occurred during the registrants most recent fiscal quarter (the
registrants fourth fiscal quarter in the case of an annual report) that has materially
affected, or is reasonably likely to materially affect, the registrants internal control
over financial reporting; and
  (a) All significant deficiencies and material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect the registrants
ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a
significant role in the registrants internal control over financial reporting.
 Dated: March 24, 2009
    By:
    /s/ DAVID E. OLSONDavid E. OlsonChief Financial Officer, Senior Vice President,
Secretary and Treasurer (Principal Financial and
Accounting Officer)
The State of

Fourth Court of Appeals

San Antonio, Texas

June 10, 2014

No. 04-13-00883-CR

Santos GUEVARA,

Appellant

v.

The STATE of Texas,

Appellee

From the 216th Judicial District Court, Gillespie County, Texas

Trial Court No. 4704

Honorable N. Keith Williams, Judge Presiding

ORDER

Appellant is represented on appeal by retained counsel, Mr. James R. Chapman. Mr. 

Chapman has already been granted one thirty-five day extension of time in which to file 

appellant’s brief, which was due June 9, 2014. Mr. Chapman has filed a second motion asking 

for an extension of time until August 9, 2014. In his motion, Mr. Chapman states there are three 

appeals, including this one, pending before this court that are all inter-related, and he intends to 

file a motion to consolidate at a future date if it is determined that appellant is indigent in the 

third appeal (04-14-00303-CR). Mr. Chapman also states that a hearing on whether appellant is 

indigent is set for June 12, 2014, in that appeal.

Accordingly, we ORDER the motion for an extension of time held in abeyance until 

further order of this court. We further ORDER Mr. Chapman to file in this court on or before 

June 19, 2014, a letter stating: (1) the outcome of the indigency hearing in appellate cause 

number 04-14-00303-CR, and (2) whether appellant intends to pursue his appeal in appellate 

cause number 04-13-00883-CR.

We further order the clerk of this court to serve a copy of this order on Mr. Chapman by 

certified mail, return receipt requested, and by regular United States mail. The clerk is also 

ordered to serve a copy of this order by facsimile to the Honorable N. Keith Williams, Presiding 

Judge, 216th Judicial District Court, Gillespie County, Texas.
_________________________________

Marialyn Barnard, Justice

IN WITNESS WHEREOF, I have hereunto set my hand and affixed the seal of the said 

court on this 10th day of June, 2014.

___________________________________

Keith E. Hottle

Clerk of Court
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1670 Sorbitol dehydrogenase test system. ( a ) *Identification.* A sorbitol dehydrogenase test system is a device intended to measure the activity of the enzyme sorbitol dehydrogenase in serum. Measurements obtained by this device are used in the diagnosis and treatment of liver disorders such as cirrhosis or acute hepatitis.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9.
[52 FR 16122, May 1, 1987, as amended at 53 FR 21449, June 8, 1988; 66 FR 38788, July 25, 2001]
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.1120 Indwelling blood oxyhemoglobin concentration analyzer. ( a ) *Identification.* An indwelling blood oxyhemoglobin concentration analyzer is a photoelectric device used to measure, in vivo, the oxygen-carrying capacity of hemoglobin in blood to aid in determining the patient's physiological status.
( b ) *Classification.* Class III (premarket approval).
( c ) Date PMA or notice of completion of PDP is required. A PMA or notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before September 21, 2004, for any indwelling blood oxyhemoglobin concentration analyzer that was in commercial distribution before May 28, 1976, or that has, on or before September 21, 2004, been found to be substantially equivalent to an indwelling blood oxyhemoglobin concentration analyzer that was in commercial distribution before May 28, 1976. Any other indwelling blood oxyhemoglobin concentration analyzer shall have an approved PMA or declared completed PDP in effect before being placed in commercial distribution.
[47 FR 31142, July 16, 1982, as amended at 52 FR 17735, May 11, 1987; 52 FR 22577, June 12, 1987; 69 FR 34920, June 23, 2004]
§ 610.44 Use of reference panels by manufacturers of test kits. ( a ) When available and appropriate to verify acceptable sensitivity and specificity, you, a manufacturer of test kits, must use a reference panel you obtain from FDA or from an FDA designated source to test lots of the following products. You must test each lot of the following products, unless FDA informs you that less frequent testing is appropriate, based on your consistent prior production of products of acceptable sensitivity and specificity: ( 1 ) A test kit approved for use in testing donations of human blood and blood components for evidence of infection due to relevant transfusion-transmitted infections under § 610.40(a); and
( 2 ) Human immunodeficiency virus (HIV) test kit approved for use in the diagnosis, prognosis, or monitoring of this relevant transfusion-transmitted infection.
( b ) You must not distribute a lot that is found to be not acceptable for sensitivity and specificity under § 610.44(a). FDA may approve an exception or alternative to this requirement. Applicants must submit such requests in writing. However, in limited circumstances, such requests may be made orally and permission may be given orally by FDA. Oral requests and approvals must be promptly followed by written requests and written approvals.
[66 FR 31164, June 11, 2001, as amended at 80 FR 29897, May 22, 2015]
# C_2016027EN.01007502.xml

| 25.1.2016 | EN | Official Journal of the European Union | C 27/75 |
| --- | --- | --- | --- |

25.1.2016

EN

Official Journal of the European Union

C 27/75

---

Order of the General Court of 11 November 2015 — salesforce.com v OHIM (MARKETINGCLOUD)

(Case T-387/14) (1)

1

(2016/C 027/95)

Language of the case: English

The President of the Second Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 261, 11.8.2014.

1

---
#### § 82.1206 D&C Green No. 6.

The color additive D&C Green No. 6 shall conform in identity and specifications to the requirements of § 74.1206 (a) and (b) of this chapter. D&C Green No. 6 is restricted to use in externally applied drugs and cosmetics.

[47 FR 14147, Apr. 2, 1982, as amended at 51 FR 9785, Mar. 21, 1986]
11 TH COURT OF APPEALS

EASTLAND

, TEXAS

JUDGMENT

Kasey Craig Melton

, * From the 132 nd District Court

of Scurry County

Trial Court No. 9321

.

Vs. No. 11

- 17

- 00011

- CR * March 8 , 2018

The State of Texas, * Memorandum Opinion by Willson , J.

(Panel consists of: Willson, J.,

Bailey, J. , and Wright, S.C.J., sitting

by assignment )

This court has inspected the record in this cause and concludes that there is

error in the judgment below. Therefore, in accordance with this court’s opinion, we

modify the judgment of the t rial court to delete the assessments of $550 for

attorney’s fe es and $3,750 for res titution. As modified, we affirm the judgment of

the tr ial court.
<TABLE> <S> <C>


<ARTICLE>                     5
                       
<MULTIPLIER>                  1
<CURRENCY>                    U.S. Dollars                
       
<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>               SEP-30-1998          
<PERIOD-START>                  OCT-01-1997    
<PERIOD-END>                    MAR-31-1998    
<EXCHANGE-RATE>                            1    
<CASH>                               166,221   
<SECURITIES>                               0   
<RECEIVABLES>                          8,325   
<ALLOWANCES>                               0   
<INVENTORY>                                0   
<CURRENT-ASSETS>                     174,546   
<PP&E>                               404,914   
<DEPRECIATION>                      (118,251)   
<TOTAL-ASSETS>                       461,209  
<CURRENT-LIABILITIES>                 28,253   
<BONDS>                                    0   
<PREFERRED-MANDATORY>                      0   
<PREFERRED>                                0   
<COMMON>                             122,146   
<OTHER-SE>                           263,772   
<TOTAL-LIABILITY-AND-EQUITY>         461,209   
<SALES>                                    0   
<TOTAL-REVENUES>                       6,000   
<CGS>                                      0   
<TOTAL-COSTS>                              0   
<OTHER-EXPENSES>                      17,128   
<LOSS-PROVISION>                           0   
<INTEREST-EXPENSE>                    (4,154)   
<INCOME-PRETAX>                      (11,128)       
<INCOME-TAX>                               0  
<INCOME-CONTINUING>                  (11,128)   
<DISCONTINUED>                        (5,428)  
<EXTRAORDINARY>                            0  
<CHANGES>                                  0   
<NET-INCOME>                         (16,556)   
<EPS-PRIMARY>                              0  
<EPS-DILUTED>                              0   
        

</TABLE>
§ 582.1099 Tartaric acid. ( a ) *Product.* Tartaric acid.
( b ) *Conditions of use.* This substance is generally recognized as safe when used in accordance with good manufacturing or feeding practice.